Allogene Therapeutics Inc (ALLO) Stock Price, Quote, News & History

ALLONASDAQ
$2.12
-0.035-1.63%
Last update: Jun 2, 3:04 PM

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-109.23M
Investing Cash Flow (TTM)
59.80M
Financing Cash Flow (TTM)
37.29M
Free Cash Flow (TTM)
-109.53M
Capital Expenditure (TTM)
-296.00K
Net Change in Cash (TTM)
-12.15M

Analyst Trends and Forecast

1
Jan
2
Mar
4
3
Apr
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$549.56M
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
-
PB Ratio (TTM)
2.67
Earnings Yield % (TTM)
-35.73%
Earnings Yield % (FWD)
-39.68%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$0.81

Company Debt

Total Debt
-
LT Debt
-
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-
Total Cash
$30.31M
Debt to Equity
0.26
Issuance of Debt (TTM)
-
Repayment of Debt (TTM)
-

Key Statistics

Open
$2.15
Close
-
Volume / Avg.
5.13M / 9.50M
Day Range
$2.04 - $2.15
52 Wk Range
0.98 - 4.46
Market Cap
$730.00M
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
46
Short Interest
13.56%
Days to Cover
6.41

About

Sector
Health Care
Industry
Biotechnology
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf"...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Allogene Therapeutics (ALLO) stock?

A

You can purchase shares of Allogene Therapeutics (NASDAQ:ALLO) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Allogene Therapeutics (ALLO) competitors?

A

There are no as such competitors for Allogene Therapeutics.

Q

What is the forecast, or price target, for Allogene Therapeutics (ALLO) stock?

A

Allogene Therapeutics has a consensus price target of $8.17.

Q

What is the current price for Allogene Therapeutics (ALLO)?

A

The stock price for Allogene Therapeutics (NASDAQ: ALLO) is $2.115 last updated June 2, 2026 at 3:04 PM EDT.

Q

Does Allogene Therapeutics (ALLO) pay a dividend?

A

There are no upcoming dividends for Allogene Therapeutics.

Q

When is Allogene Therapeutics (NASDAQ:ALLO) reporting earnings?

A

Allogene Therapeutics does not have any upcoming earnings scheduled.

Q

Is Allogene Therapeutics (ALLO) going to split?

A

There is no upcoming split for Allogene Therapeutics.

Q

What sector and industry does Allogene Therapeutics (ALLO) operate in?

A

Allogene Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.